Organization | EUCLID

EUCLID Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Apple Creek OH United States (1980)

Organization Overview

First Clinical Trial

2016

NCT02658253

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

EUCLID | EUCLID Clinical Trial Platform | EUCLID Clinical Trials Platform

Active Ingredients

Drugs in Phase 3 Trials (2)

serogroup b meningococcal vaccine (Trumenba) (1 trial)

serogroup B meningococcal vaccine (Bexsero) (1 trial)

Drugs in Phase 2 Trials (4)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (2 trials)

lixisenatide (adlyxin) (1 trial)

pimavanserin (nuplazid) (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (2 trials)

Drugs in Phase 1 Trials (2)

aluminum hydroxide (Gaviscon) (1 trial)

placental malaria vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 2)

Disruptive, Impulse Control, and Conduct Disorders (Phase 2)

Malaria (Phase 1)

Parkinson Disease (Phase 2)

Pneumococcal Infections (Phase 2)

Vasculitis (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 8